Use: Labeled indications
- ILUMYA is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- active psoriatic arthritis in adult patients.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ILUMYA is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. (1.1) active psoriatic arthritis in adult patients. (1.2) 1.1 Moderate-to-Severe Plaque Psoriasis ILUMYA ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 1.2 Active Psoriatic Arthritis ILUMYA is indicated for the treatment of active psoriatic arthritis in adult patients.
Contraindications
4 CONTRAINDICATIONS ILUMYA is contraindicated in patients with a history of serious hypersensitivity reaction to tildrakizumab or to any of the excipients [see Warnings and Precautions (5.1)]. Serious hypersensitivity reaction to tildrakizumab or to any of the excipients. (4)
US FDA labelDosing: Adult
- See the full prescribing information for recommended evaluations and immunizations prior to treatment. (2.1)
- Administer ILUMYA by subcutaneous injection. (2.2)
- Recommended dosage: Moderate-to-Severe Plaque Psoriasis 100 mg at Weeks 0, 4, and every 12 weeks thereafter. (2.2)
- Active Psoriatic Arthritis For adult patients with active psoriatic arthritis and coexistent moderate-to-severe plaque psoriasis, the recommended dosage is the same as in adults with moderate-to-severe plaque psoriasis. For other adult patients with active psoriatic arthritis: 100 mg every 12 weeks. (2.2)
2.1 Recommended Evaluation and Immunization Prior to Treatment Initiation
2.1 Recommended Evaluation and Immunization Prior to Treatment Initiation Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA [see Warnings and Precautions (5.3)]. Consider completion of all age appropriate immunizations according to current immunization guidelines. [see Warnings and Precautions (5.4)]
2.2 Recommended Dosage in Adults with Moderate-to-Severe Plaque Psoriasis and Active
2.2 Recommended Dosage in Adults with Moderate-to-Severe Plaque Psoriasis and Active Psoriatic Arthritis Administer ILUMYA as a subcutaneous injection. Moderate-to-Severe Plaque Psoriasis The recommended dosage in adult patients with moderate-to-severe plaque psoriasis is 100 mg at Weeks 0, 4, and every 12 weeks thereafter.
Active Psoriatic Arthritis For adult patients with active psoriatic arthritis and coexistent moderate-to-severe plaque psoriasis, the recommended dosage is the same as in adults with moderate-to-severe plaque psoriasis. For other adult patients with active psoriatic arthritis, the recommended dosage is 100 mg every 12 weeks.
2.3 Important Administration Instructions
2.3 Important Administration Instructions ILUMYA should only be administered by a healthcare provider. Administer ILUMYA subcutaneously. Each prefilled syringe is for single-dose only. Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe. If a dose is missed, administer the dose as soon as possible.
Thereafter, resume dosing at the regularly scheduled interval.
2.4 Preparation and Administration
2.4 Preparation and Administration of ILUMYA Before injection, remove ILUMYA carton from the refrigerator, and let the prefilled syringe (in the ILUMYA carton with the lid closed) sit at room temperature for 30 minutes. Follow the instructions on the ILUMYA carton to remove the prefilled syringe correctly, and remove only when ready to inject.
Do not pull off the needle cover until you are ready to inject. Inspect ILUMYA visually for particulate matter and discoloration prior to administration. ILUMYA is a clear to slightly opalescent, colorless to slightly yellow solution. Do not use if the liquid contains visible particles or the syringe is damaged. Air bubbles may be present; there is no need to remove them.
Choose an injection site with clear skin and easy access (such as abdomen, thighs, or upper arm). Do not administer 2 inches around the navel or where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Also, do not inject into scars, stretch marks, or blood vessels. While holding the body of the syringe, pull the needle cover straight off (do not twist) and discard.
Inject ILUMYA subcutaneously as recommended [see Dosage and Administration (2.3)]. Press down the blue plunger until it can go no further. This activates the safety mechanism that will ensure full retraction of the needle after the injection is given. Remove the needle from the skin entirely before letting go of the blue plunger.
After the blue plunger is released, the safety lock will draw the needle inside the needle guard. Discard any unused portion. Dispose of used syringe. image-1 image-2 image-3
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of ILUMYA in pediatric patients (<18 years of age) have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use A total of 1083 subjects with plaque psoriasis were exposed to ILUMYA 100 mg during Phase 2 and 3 trials. A total of 92 subjects were 65 years and older, and 17 subjects were 75 years and older. A total of 481 subjects with psoriatic arthritis were exposed to ILUMYA 100 mg during Phase 2 and 3 trials. A total of 86 subjects were 65 years and older.
Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they responded differently from younger subjects [see Clinical Pharmacology (12.3)].
Administration
2.3 Important Administration Instructions ILUMYA should only be administered by a healthcare provider. Administer ILUMYA subcutaneously. Each prefilled syringe is for single-dose only. Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe. If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regularly scheduled interval.
2.4 Preparation and Administration of ILUMYA Before injection, remove ILUMYA carton from the refrigerator, and let the prefilled syringe (in the ILUMYA carton with the lid closed) sit at room temperature for 30 minutes. Follow the instructions on the ILUMYA carton to remove the prefilled syringe correctly, and remove only when ready to inject. Do not pull off the needle cover until you are ready to inject. Inspect ILUMYA visually for particulate matter and discoloration prior to administration. ILUMYA is a clear to slightly opalescent, colorless to slightly yellow solution. Do not use if the liquid contains visible particles or the syringe is damaged. Air bubbles may be present; there is no need to remove them. Choose an injection site with clear skin and easy access (such as abdomen, thighs, or upper arm). Do not administer 2 inches around the navel or where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Also, do not inject into scars, stretch marks, or blood vessels. While holding the body of the syringe, pull the needle cover straight off (do not twist) and discard. Inject ILUMYA subcutaneously as recommended [see Dosage and Administration (2.3) ] . Press down the blue plunger until it can go no further. This activates the safety mechanism that will ensure full retraction of the needle after the injection is given. Remove the needle from the skin entirely before letting go of the blue plunger. After the blue plunger is released, the safety lock will draw the needle inside the needle guard. Discard any unused portion. Dispose of used syringe. image-1 image-2 image-3
US FDA labelDosage forms
Philippines
- Solution for injection: 100 mg/mL
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Tildrakizumab as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
IlumyaTildrakizumab | 100 mg/mL Solution for Injection (S.C.)1 mL Single-Dose Prefilled Syringe With A Glass Barrel And 29-Gauge Fixed, 1/2-Inch Needle, Fitted With A Passive Needle Guard And Needle Cover, Packaged Into A Tray, And Placed Inside A Carton Box. | Rx | Vetter Pharma-Fertigung GmbH & Co. KGIndia | Sun Pharma Philippines, Inc.Trader: Sun Pharmaceutical Industries Limited | BR-1419 | Sep 13, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/mL solution in a single-dose prefilled syringe. ILUMYA is a clear to slightly opalescent, colorless to slightly yellow solution. Injection: 100 mg/mL solution in a single-dose prefilled syringe. (3)
Warnings/Precautions
- Hypersensitivity: If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. (5.1)
- Infections: ILUMYA may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, consider discontinuing ILUMYA until the infection resolves. (5.2)
- Pretreatment Evaluation for Tuberculosis (TB): Evaluate for TB prior to initiating treatment. (5.3)
- Immunizations: Avoid use of live vaccines. (5.4)
5.1 Hypersensitivity
5.1 Hypersensitivity Cases of angioedema and urticaria occurred in ILUMYA treated subjects in clinical trials. If a serious hypersensitivity reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy [see Adverse Reactions (6.1)].
5.2 Infections
5.2 Infections ILUMYA may increase the risk of infection. In subjects with plaque psoriasis, although infections were more common in the ILUMYA group (23%), the difference in frequency of infections between the ILUMYA group and the placebo group (22%) was less than 1% during the placebo-controlled period. However, subjects with active infections or a history of recurrent infections were not included in clinical trials.
Upper respiratory infections occurred more frequently in the ILUMYA group than in the placebo group [see Adverse Reactions (6.1)]. In subjects with plaque psoriasis, the rates of serious infections for the ILUMYA group and the placebo group were ≤0.3%. In subjects with psoriatic arthritis, infections were more common in the ILUMYA 100 mg group (31%) than in the placebo group (28%) during the 24-week placebo-controlled period.
The rates of serious infections for the ILUMYA group and the placebo group were 0.4% and 0%, respectively. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ILUMYA. Instruct patients to seek medical help if signs or symptoms of clinically important chronic or acute infection occur.
If a patient develops a clinically important or serious infection or is not responding to standard therapy, monitor the patient closely and consider discontinuation of ILUMYA until the infection resolves [see Adverse Reactions (6.1)].
5.3 Tuberculosis
5.3 Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. In clinical trials in subjects with plaque psoriasis, of 55 subjects with latent TB who were concurrently treated with ILUMYA and appropriate TB prophylaxis, no subjects developed active TB (during the mean follow-up of 56.5 weeks).
One other subject developed TB while receiving ILUMYA. In clinical trials in subjects with psoriatic arthritis, of 35 subjects with latent TB who were concurrently treated with ILUMYA and appropriate TB prophylaxis, no subjects developed active TB (during the mean follow-up of 87.0 weeks). However, one subject who did not have latent TB developed active TB while receiving ILUMYA.
Monitor patients for signs and symptoms of active TB during and after ILUMYA treatment. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
5.4 Immunizations
5.4 Immunizations Prior to initiating therapy with ILUMYA, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with ILUMYA. No data are available on the response to live or inactive vaccines.
Drug interactions
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Drug Interaction Studies Cytochrome P450 Substrates The AUC inf of dextromethorphan (CYP2D6 substrate) increased by 20% when used concomitantly with tildrakizumab 200 mg (two times the approved recommended dose) administered subcutaneously at Weeks 0 and 4 in subjects with plaque psoriasis.
No clinically significant changes in AUC inf of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate) were observed.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Infections [see Warnings and Precautions (5.2)] Most common adverse reactions associated with ILUMYA treatment are Plaque Psoriasis (≥1%): upper respiratory infections, injection site reactions, and diarrhea. (6.1) Psoriatic Arthritis (≥3%): upper respiratory tract infections and COVID-19.
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Plaque Psoriasis In clinical trials, a total of 1994 subjects with plaque psoriasis were treated with ILUMYA, of which 1083 subjects were treated with ILUMYA 100 mg.
Of these, 672 subjects were exposed for at least 12 months, 587 for 18 months, and 469 for 24 months. Data from three placebo-controlled trials (Trials 1, 2, and 3) in 705 subjects (mean age 46 years, 71% males, 81% white) were pooled to evaluate the safety of ILUMYA (100 mg administered subcutaneously at Weeks 0 and 4, followed by every 12 weeks [Q12W]) [see Clinical Studies (14)].
Placebo-Controlled Period (Weeks 0-16 of Trial 1 and Weeks 0-12 of Trials 2 and 3) Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the ILUMYA group than in the placebo group. Table 1: Adverse Reactions Occurring in ≥1% of Subjects in the ILUMYA Group and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3 * Upper respiratory infections include nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. † Injection site reactions include injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, and hemorrhage.
Adverse Reaction ILUMYA Placebo 100 mg (N=705) (N=355) N (%) N (%) Upper respiratory infections* 98 (14) 41 (12) Injection site reactions † 24 (3) 7 (2) Diarrhea 13 (2) 5 (1) During the placebo-controlled period of Trials 1, 2, and 3, adverse reactions that occurred at rates less than 1% but greater than 0.1% in the ILUMYA group and at a higher rate than in the placebo group included dizziness and pain in extremity. Cases of angioedema and urticaria were reported in ILUMYA-treated subjects in clinical trials.
Safety through Week 260 The safety profile of ILUMYA through Week 260 of the open-label extension periods of Trial 2 and Trial 3 was consistent with the safety profile observed during the double-blind periods. Psoriasis of the Scalp The safety of ILUMYA was assessed in a multicenter, randomized, double-blind, placebo-controlled trial (Trial 4) in 231 subjects with psoriasis of the scalp [see Clinical Studies (14)].
No new safety signals were identified through follow-up to Week 72. Psoriasis of the Nail The safety of ILUMYA was assessed in a multicenter, randomized, double-blind, placebo-controlled trial (Trial 5) in 99 subjects with psoriasis of the nail [see Clinical Studies (14)]. No new safety signals were identified through Week 28.
Psoriatic Arthritis In clinical trials, a total of 716 subjects with active psoriatic arthritis (PsA) were treated with ILUMYA, of which 481 subjects were treated with ILUMYA 100 mg. Of these, 281 subjects were exposed for at least 12 months, 251 for 18 months, and 188 for 24 months. Data from the placebo-controlled periods of one Phase 2 study (Trial PsA1) and two Phase 3 studies (Trial PsA2 and Trial PsA3) in 481 subjects treated with ILUMYA 100 mg every 12 weeks and 478 subjects treated with placebo were pooled to evaluate the safety of ILUMYA through Week 24.
The overall safety profile was consistent with that observed in adults with moderate-to-severe plaque psoriasis. Placebo-Controlled Period (Week 0 through Week 24) Table 2 summarizes the adverse reactions that occurred at a rate of at least 3% and at a higher rate in the ILUMYA group than in the placebo group. Table 2: Adverse Reactions Occurring in ≥3% of Subjects in the ILUMYA Group and More Frequently than in the Placebo Group in the Psoriatic Arthritis Trial PsA1, Trial PsA2 and Trial PsA3 Adverse Reaction ILUMYA 100 mg (N=481) N (%) Placebo (N=478) N (%) Upper respiratory tract infections 23 (4.8) 21 (4.4) COVID-19 26 (5.4) 21 (4.4)
Adverse reaction frequency tables (US label) US FDA label
| Table 1: Adverse Reactions Occurring in ≥1% of Subjects in the ILUMYA Group and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3 | ||
|---|---|---|
| * Upper respiratory infections include nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. † Injection site reactions include injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, and hemorrhage. | ||
| Adverse Reaction | ILUMYA | Placebo |
| 100 mg | ||
| (N=705) | (N=355) | |
| N (%) | N (%) | |
| Upper respiratory infections* | 98 (14) | 41 (12) |
| Injection site reactions† | 24 (3) | 7 (2) |
| Diarrhea | 13 (2) | 5 (1) |
| Adverse Reaction | ILUMYA 100 mg (N=481) N (%) | Placebo (N=478) N (%) |
|---|---|---|
| Upper respiratory tract infections | 23 (4.8) | 21 (4.4) |
| COVID-19 | 26 (5.4) | 21 (4.4) |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors outcomes in women with plaque psoriasis or active psoriatic arthritis who become pregnant while being treated with ILUMYA during pregnancy. These patients can enroll in this registry by calling MotherToBaby a service of the Organization of Teratology Information Specialists (OTIS) at 1-866-626-6847 or by visiting the website https://mothertobaby.org/ongoing-study/ilumya-tildrakizumab-asmn.
Risk Summary Available data from clinical trials, published literature, and pharmacovigilance with ILUMYA use in pregnant women are insufficient to inform a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Monoclonal antibodies are actively transported across the placenta (see Clinical Considerations).
An embryofetal developmental study conducted with tildrakizumab in pregnant monkeys revealed no treatment-related effects to the developing fetus when tildrakizumab was administered subcutaneously during organogenesis to near parturition at doses up to 159 times the maximum recommended human dose (MRHD). When dosing was continued until parturition, an increase in neonatal death was observed at 59 times the MRHD (see Data).
The clinical significance of this nonclinical finding is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations Fetal/Neonatal Adverse Reactions Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester. Therefore, ILUMYA may be present in infants exposed in utero. The potential clinical impact of tildrakizumab exposure in infants exposed in utero should be considered.
Data Animal Data In an embryofetal developmental study, subcutaneous doses up to 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during organogenesis to gestation day 118 (22 days from parturition). No maternal or embryofetal toxicities were observed at doses up to 300 mg/kg (159 times the MRHD of 100 mg, based on AUC comparison).
Tildrakizumab crossed the placenta in monkeys. In a pre- and postnatal developmental study, subcutaneous doses up to 100 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks from gestation day 50 to parturition. Neonatal deaths occurred in the offspring of one control monkey, two monkeys at 10 mg/kg dose (6 times the MRHD based on AUC comparison), and four monkeys at 100 mg/kg dose (59 times the MRHD based on AUC comparison).
The clinical significance of these nonclinical findings is unknown. No tildrakizumab-related adverse effects were noted in the remaining infants from birth through 6 months of age.
Mechanism of action
12.1 Mechanism of Action Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics No formal pharmacodynamics studies have been conducted with ILUMYA.
Pharmacokinetics
Elimination The geometric mean (CV%) systemic clearance was 0.32 L/day (38%) and the half-life was approximately 23 days (23%).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Tildrakizumab pharmacokinetics (PK) increases proportionally over a dose range from 50 mg to 200 mg (0.5 to 2 times the approved recommended dosage) following subcutaneous administration in subjects with plaque psoriasis. Steady-state concentrations were achieved by Week 16 following subcutaneous administration of tildrakizumab at Weeks 0, 4, and every 12 weeks thereafter.
At the 100 mg dose at Week 16, the mean (± SD) steady-state trough concentrations ranged from 1.22 ± 0.94 mcg/mL to 1.47 ± 1.12 mcg/mL. The geometric mean (CV%) steady-state C max was 8.1 mcg/mL (34%). The PK characteristics of tildrakizumab in subjects with psoriatic arthritis were similar to that in subjects with plaque psoriasis.
In patients with psoriatic arthritis who received subcutaneous treatment with ILUMYA 100 mg every 12 weeks, the geometric means (%CV) of AUC 0-tau, C max, and C trough at steady state were 317 mcg*day/mL (42.6%), 8.52 mcg/mL (37.7%), and 0.89 mcg/mL (86.2%), respectively. Absorption The absolute bioavailability of tildrakizumab was estimated to be 73-80% following subcutaneous injection.
The peak concentration (C max) was reached by approximately 6 days. Distribution The geometric mean (CV%) volume of distribution is 10.8 L (24%). Elimination The geometric mean (CV%) systemic clearance was 0.32 L/day (38%) and the half-life was approximately 23 days (23%). Metabolism The metabolic pathway of tildrakizumab has not been characterized.
As a humanized IgG1/k monoclonal antibody, tildrakizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG. Specific Populations No clinically significant differences in the pharmacokinetics of tildrakizumab were observed based on age (≥18 years).
No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of tildrakizumab. Body Weight Tildrakizumab concentrations were lower in subjects with higher body weight. Drug Interaction Studies Cytochrome P450 Substrates The AUC inf of dextromethorphan (CYP2D6 substrate) increased by 20% when used concomitantly with tildrakizumab 200 mg (two times the approved recommended dose) administered subcutaneously at Weeks 0 and 4 in subjects with plaque psoriasis.
No clinically significant changes in AUC inf of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate) were observed.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ILUMYA · Sun Pharmaceutical Industries, Inc. [US FDA-approved label, version 21, November 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6a322bb-51b9-4f0e-8642-62a9682ffcde
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .